MDP stands for methylene diphosphonate.
Bone tissue consists of more flexible and organic part called 'ossein' or 'matrix' (~30% by mass) and the mineral or inorganic part (~70% by mass). Ossein largely consists of collagen fibres. Inorganic part largely consists of 'apatite' (a phosphate-containing molecule) and the metal calcium. The inorganic part tends to form crystals called 'calcium hydroxyapatite'.
Although bones are very strong and appear like solid permanent structures, in reality any bone is constantly added to (through cells called 'osteoblasts') and broken down (through cells called 'osteoclasts'). In a healthy state these mutually antagonistic processes are in a state of equilibrium, and are part of 'bone metabolism'.
Newly formed (immature) bone tends to have more numerous but smaller hydroxyapatite crystals in contrast to the mature bone that has larger crystals. Smaller crystals of immature bone have overall greater surface area and empty sites for binding of molecules like MDP. In some of the disease processes, blood supply to the abnormal tissues around the bone is also increased. Thus, binding of MDP to bone is increased by: (a) presence of sites of immature bone, and (b) increased blood supply.
Tumours developing primarily in bone as well as those that would have developed following spread from cancers at other sites ('metastases') harbour large proportion of immature bone because of fast rate of bone formation. Same holds true for sites of recent as well as old fractures, bone infections and non-cancerous causes of excessive bone formation.
There are no remarkable expected risks or side effects.
For additional information, please visit the following links.